Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | PLK1 | P53350 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954191 | 0.86 | GAA (0.57) | HPGDGAALMNAL3MBTL1PLK1 | |
| SCHEMBL11743421 | 0.85 | GAA (0.52) | HPGDGAALMNAL3MBTL1PLK1 | |
| SCHEMBL2537984 | 0.82 | GAA (0.53) | HPGDGAALMNAL3MBTL1PLK1 | |
| SCHEMBL17629659 | 0.82 | GAA (0.53) | HPGDGAALMNAL3MBTL1PLK1 | |
| SCHEMBL16597336 | 0.82 | GAA (0.53) | HPGDGAALMNAL3MBTL1PLK1 | |
| SCHEMBL8339183 | 0.82 | GAA (0.53) | HPGDGAALMNAL3MBTL1PLK1 | |
| SCHEMBL4763592 | 0.82 | GAA (0.53) | HPGDGAALMNAL3MBTL1PLK1 | |
| SCHEMBL3412935 | 0.82 | GAA (0.62) | HPGDGAALMNAL3MBTL1NPC1 | |
| SCHEMBL1098843 | 0.82 | GAA (0.62) | HPGDGAALMNAL3MBTL1NPC1 | |
| SCHEMBL13705878 | 0.81 | GAA (0.52) | HPGDGAALMNAL3MBTL1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3638229-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-6806279-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, UVEITIS, AND PSORIASIS, ALLOGRAFT REJECTION, AND GRAFT-VERSUS-HOST DISEASE | SUNESIS PHARMACEUTICALS, INC. | 2004-10-19 | — | — | US | disclosed |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | SUNESIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051797-A2 | SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-4175191-A | 4-Phenyl isoquinolines | SANDOZ, INC. (US) | 1979-11-20 | — | — | US | disclosed |
| US-3989704-A | 3-Substituted-4-aryl isoquinolines | SANDOZ, INC. (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | HPGD 3505/4885GAA 523/4885LMNA 4086/4885 |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | HPGD 3343/4885GAA 4673/4885LMNA 607/4885 |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | IL2, IL2RA, HLA-DRB1 | HPGD 669/4885GAA 4050/4885LMNA 4800/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | HPGD 1152/4885GAA 3551/4885LMNA 4867/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | HPGD 3343/4885GAA 4673/4885LMNA 607/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | HPGD 3505/4885GAA 523/4885LMNA 4086/4885 |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | HPGD 3825/4885GAA 546/4885LMNA 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.